NF-κB Signaling Pathway Inhibitors as Anticancer Drug Candidates

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Nuclear factor kappa B (NF-κB) is a transcription factor regulating key cellular processes like proliferation, survival, and apoptosis.
• Constitutive activation and/or overexpression of NF-κB are common in various hematological malignancies and solid tumors.
• NF-κB pathway activation contributes to chemoresistance and radioresistance in cancer treatment.

Purpose of the Study:

• To review research on novel inhibitors targeting the NF-κB signaling pathway.
• To highlight the potential of NF-κB inhibitors as anticancer drug candidates.
• To discuss the role of NF-κB inhibition in overcoming cancer treatment resistance.

Main Methods:

• Literature review of studies identifying NF-κB signaling pathway inhibitors.
• Analysis of research on the therapeutic potential of these inhibitors in cancer.
• Synthesis of information regarding NF-κB's role in cancer progression and resistance.

Main Results:

• NF-κB plays a critical role in cancer cell proliferation, survival, and metastasis.
• Inhibition of the NF-κB pathway demonstrates potential in enhancing the efficacy of chemotherapy and radiotherapy.
• Identification of novel NF-κB inhibitors as promising therapeutic agents.

Conclusions:

• Targeting the NF-κB signaling pathway is a viable strategy for developing new anticancer drugs.
• Inhibiting NF-κB can potentially overcome acquired resistance to current cancer therapies.
• Further research into NF-κB inhibitors is warranted for clinical application in oncology.